Since its introduction in the late 1970s for the treatment of strabismus and blepharospasm, botulinum toxin (BoNT) has been increasingly used in the interventional treatment of several other disorders characterized by excessive or inappropriate muscle contractions. Over the years, the number of primary clinical publications has grown exponentially, and still continues to increase. It has been shown that BoNT blocks cholinergic nerve endings in the autonomic nervous system but does not block non-adrenergic non-cholinergic responses mediated by nitric oxide (NO). The present paper reviews a number of recent clinical indications for urological and pelvic floor dysfunctions, such as overactive and neurogenic bladder, non-bacterial prostatitis, benign prostatic hyperplasia, chronic anal fissure, or conditions associated to hyperactivity of the puborectalis muscle during straining. These indications provide a new promising palette of indications for future usage of BoNT in clinical practice.

Brisinda, G., Maria, G., Bentivoglio, A., Cadeddu, F., Marniga, G., Brandara, F., et al. (2006). Management of bladder, prostatic and pelvic floor disorders. NEUROTOXICITY RESEARCH, 9(2-3), 161-172.

Management of bladder, prostatic and pelvic floor disorders

CADEDDU, FEDERICA;
2006-04-01

Abstract

Since its introduction in the late 1970s for the treatment of strabismus and blepharospasm, botulinum toxin (BoNT) has been increasingly used in the interventional treatment of several other disorders characterized by excessive or inappropriate muscle contractions. Over the years, the number of primary clinical publications has grown exponentially, and still continues to increase. It has been shown that BoNT blocks cholinergic nerve endings in the autonomic nervous system but does not block non-adrenergic non-cholinergic responses mediated by nitric oxide (NO). The present paper reviews a number of recent clinical indications for urological and pelvic floor dysfunctions, such as overactive and neurogenic bladder, non-bacterial prostatitis, benign prostatic hyperplasia, chronic anal fissure, or conditions associated to hyperactivity of the puborectalis muscle during straining. These indications provide a new promising palette of indications for future usage of BoNT in clinical practice.
apr-2006
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/18 - CHIRURGIA GENERALE
English
Con Impact Factor ISI
Pelvic Floor; Animals; Botulinum Toxins; Urologic Diseases; Prostatic Diseases; Neuromuscular Diseases; Humans; Urinary Bladder Diseases; Rectal Diseases; Male
PMID: 16785114
Brisinda, G., Maria, G., Bentivoglio, A., Cadeddu, F., Marniga, G., Brandara, F., et al. (2006). Management of bladder, prostatic and pelvic floor disorders. NEUROTOXICITY RESEARCH, 9(2-3), 161-172.
Brisinda, G; Maria, G; Bentivoglio, A; Cadeddu, F; Marniga, G; Brandara, F; Albanese, A
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/35021
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact